Phenoxazine derivatives 2-amino-4,4α-dihydro-4α-phenoxazine-3- one and 2-aminophenoxazine-3-one-induced apoptosis through a caspase-independent mechanism in human neuroblastoma cell line NB-1 cells

Biological and Pharmaceutical Bulletin

Volumn 30, Issue 2, 2007, Pages 331-336

  Shirato, Ken ^a   Imaizumi, Kazuhiko ^a   Abe, Akihisa ^b   Tomoda, Akio ^b  

^a WASEDA UNIVERSITY   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Apopotosis; Caspase 3 7; Neuroblastoma cell line; Phenoxazine; Viability inhibition

Indexed keywords

2 AMINO 3 PHENOXAZINONE; 2 AMINO 4,4ALPHA DIHYDRO 4ALPHA PHENOXAZIN 3 ONE; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE 3; CASPASE 7; PHENOXAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG STRUCTURE; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; METASTASIS; MITOSIS INHIBITION; NEUROBLASTOMA; NEUROBLASTOMA CELL;

AMINO ACID CHLOROMETHYL KETONES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; NECROSIS; NEUROBLASTOMA; OXAZINES;

EID: 33846969160     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.30.331     Document Type: Article

References (33)

1. Matthay K. K., Villablanca J. G., Seeger R. C., Stram D. O., Harris R. E., Ramsay N. K., Swift P., Shimada H., Black C. T., Brodeur G. M., Gerbing R. B., Reynolds C. P., N. Engl. J. Med., 341, 1165-1173 (1999).
2. Landis S. H., Murray T., Bolden S., Wingo P. A., CA Cancer J. Clin., 49, 8-31 (1999).
3. Goldsmith K. C., Hogarty M. D., Cancer Lett., 228, 133-141 (2005).
4. Green D. R., Reed J. C., Science, 281, 1309-1312 (1998).
5. Hollstein U., Chem. Rev., 74, 625-652 (1974).
6. Tomoda A., Arai S., Ishida R., Shimamoto T., Ohyashiki K., Bioorg. Med. Chem. Lett., 11, 1057-1058 (2001).
7. Shimizu S., Suzuki M., Tomoda A., Arai S., Taguchi H., Hanawa T., Kamiya S., Tohoku J. Exp. Med., 203, 47-52 (2004).
8. Mori H., Honda K., Ishida R., Nohira T., Tomoda A., Anticancer Drugs, 11, 653-657 (2000).
9. Shimamoto T., Tomoda A., Ishida R., Ohyashiki K., Clin. Cancer Res., 7, 704-708 (2001).
10. Gao S., Takano T., Sada K., He J., Noda C., Hori-Tamura N., Tomoda A., Yamamura H., Br. J. Pharmacol., 137, 749-755 (2002).
11. Enoki E., Sada K., Qu X., Kyo S., Miah S. M., Hatani T., Tomoda A., Yamamura H., J. Pharmacol. Sci., 94, 329-333 (2004).
12. Uruma T., Yamaguchi H., Fukuda M., Kawakami H., Goto H., Kishimoto T., Yamamoto Y., Tomoda A., Kamiya S., J. Med. Microbiol., 54, 1143-1149 (2005).
13. Iwata A., Yamaguchi T., Sato K., Yoshitake N., Tomoda A., Biol. Pharm. Bull., 28, 905-907 (2005).
14. Abe A., Yamane M., Tomoda A., Anticancer Drugs, 12, 377-382 (2001).
15. Koshibu-Koizumi J., Akazawa M., Iwamoto T., Takasaki M., Mizuno F., Kobayashi R., Abe A., Tomoda A., Hamatake M., Ishida R., J. Cancer Res. Clin. Oncol., 128, 363-368 (2002).
16. Shimizu S., Suzuki M., Miyazawa K., Yokoyama T., Ohyashiki K., Miyazaki K., Abe A., Tomoda A., Oncol. Rep., 14, 41-46 (2005).
17. Kato S., Shirato K., Imaizumi K., Toyota H., Mizuguchi J., Odawara M., Che X. F., Akiyama S., Abe A., Tomoda A., Oncol. Rep., 15, 843-848 (2006).
18. Andree H. A., Reutelingsperger C. P., Hauptmann R., Hemker H. C., Hermens W. T., Willems G. M., J. Biol. Chem., 265, 4923-4928 (1990).
19. Barry M. A., Behnke C. A., Eastman A., Biochem. Pharmacol., 40, 2353-2362 (1990).
20. Ishida R., Yamanaka S., Kawai H., Ito H., Iwai M., Nishizawa M., Hamatake M., Tomoda A., Anticancer Drugs, 7, 591-595 (1996).
21. Thornberry N. A., Lazebnik Y., Science, 281, 1312-1316 (1998).
22. Hengartner M. O., Nature (London), 407, 770-776 (2000).
23. Vanderhaeghe H., Claesen M., Kolosy P., Boll. Chim. Farm., 101, 762-765 (1962).
24. Blank B., Baxter L. L., J. Med. Chem., 11, 807-811 (1968).
25. Sen S., D'Incalci M., Fed. Eur. Biochem. Soc., 307, 122-127 (1992).
26. Lorenzo H. K., Susin S. A., Penninger J., Kroemer G., Cell Death Differ., 6, 516-524 (1999).
27. Vande Velde C., Cizeau J., Dubik D., Alimonti J., Brown T., Israels S., Hakem R., Greenberg A. H., Mol. Cell Biol., 20, 5454-5468 (2000).
28. Hong S. J., Dawson T. M., Dawson V. L., Trends Pharmacol. Sci., 25, 259-264 (2004).
29. Hail N., Jr., Carter B. Z., Konopleva M., Andreeff M., Apoptosis, 11, 889-904 (2006).
30. Tobey R. A., Nature (London), 254, 245-247 (1975).
31. Miyano-Kurosaki N., Kurosaki K., Hayashi M., Takaku H., Hayafune M., Shirato K., Kasuga T., Endo T., Tomoda A., Biol. Pharm. Bull., 29, 2197-2201 (2006).
32. Eckert K. G., Eyer P., Biochem. Pharmacol., 32, 1019-1027 (1983).
33. Azuine M. A., Tokuda H., Takayasu J., Enjyo F., Mukainaka T., Konoshima T., Nishino H., Kapadia G. J., Pharmacol. Res., 49, 161-169 (2004).